01861-A: Preventing Heart Damage during Chemotherapy through Early Detection of Cardiotoxicity

Grant Status: Closed

Grant Amount: $12,960
Leigh G. Griffiths, DVM; University of California, Davis
August 1, 2012 - April 30, 2014


Breed(s): -All Dogs
Research Program Area: Oncology
Donate to Support this Research Program Area


Doxorubicin is a commonly used chemotheraputic agent in veterinary oncology with efficacy in the treatment of many cancer types. It has been well documented that doxorubicin can cause toxic changes to the heart that can result in heart failure and even death. Abnormal heart rhythms can also occur, however in veterinary medicine, the extent of these abnormal heart rhythms has not been well documented. The purpose of this study is to evaluate the effect of doxorubicin on the occurrence of abnormal heart rhythms. The study additionally aims to evaluate the use of a biomarker for heart damage (cardiac Troponin I), as a measure of early heart muscle damage due to Doxorubicin toxicity and to determine whether serum level of this biomarker are correlated with early changes in heart function.


None at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2018 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software